糖鎖生物学グライコミクス/グリコバイオロジーの世界市場予測（～2021）：製品別（酵素（グリコシルトランスフェラーゼ、グリコシダーゼ）、機器別（高速液体クロマトグラフィー(HPLS)、質量分析、マトリックス支援レーザー脱離イオン化-飛行時間型質量分析(MALDITOF)）、キットおよび試薬別（糖タンパク質））、用途別（診断、創薬、腫瘍学）、エンドユーザー 別...市場調査レポートについてご紹介

TABLE OF CONTENTS

1 INTRODUCTION 13
1.1 OBJECTIVES OF THE STUDY 13
1.2 MARKETS DEFINITION 13
1.3 MARKETS COVERED 14
1.3.1 YEARS CONSIDERED FOR THE STUDY 14
1.4 CURRENCY 15
1.5 MARKET SCOPE 15
1.6 MARKET STAKEHOLDERS 15
2 RESEARCH METHODOLOGY 16
2.1 MARKET SIZE ESTIMATION 17
2.2 MARKET BREAKDOWN AND DATA TRIANGULATION 20
2.3 MARKET SHARE ESTIMATION 21
2.3.1 KEY DATA FROM SECONDARY SOURCES 21
2.3.2 KEY DATA FROM PRIMARY SOURCES 22
2.3.3 ASSUMPTIONS FOR THE STUDY 22
3 EXECUTIVE SUMMARY 23
4 PREMIUM INSIGHTS 28
4.1 GLYCOMICS: MARKET OVERVIEW (2016-2021) 28
4.2 GEOGRAPHIC ANALYSIS: GLYCOMICS MARKET, BY PRODUCT 29
4.3 LIFE CYCLE ANALYSIS, BY REGION 30
5 MARKET OVERVIEW 31
5.1 INTRODUCTION 32
5.2 MARKET DYNAMICS 32
5.2.1 DRIVERS 33
5.2.1.1 Increase in Funding for Proteomics and Glycomics Research, Growing R&D Expenditure 33
5.2.1.1 Growth of the Proteomics Market 33
5.2.1.2 Technological Advancements in Glycomics Instrumentation 34
5.2.2 RESTRAINTS 34
5.2.2.1 High Degree of Consolidation Hinders Entry of New Players to the Market 34
5.2.2.2 Stringent Regulatory Frameworks and Time-consuming Approval Processes 34
 
5.2.3 OPPORTUNITIES 35
5.2.3.1 Increased Use of Personalized Medicine 35
5.2.3.2 Biomarker Identification 35
5.2.3.3 Developing Countries and Emerging Markets 36
5.2.4 CHALLENGES 36
5.2.4.1 High Costs of Tools & Instruments and Their Maintenance 36
6 GLYCOMICS MARKET, BY PRODUCT 37
6.1 INTRODUCTION 38
6.2 ENZYMES 39
6.2.1 GLYCOSIDASES 40
6.2.2 GLYCOSYLTRANSFERASES 41
6.2.3 NEURAMINIDASES 41
6.2.4 SIALYLTRANSFERASES 42
6.2.5 OTHER GLYCOMICS ENZYMES 43
6.3 INSTRUMENTS 44
6.3.1 ANTIBODY ARRAYS 45
6.3.2 HPLC 46
6.3.3 LECTIN ARRAYS 47
6.3.4 MALDI-TOF 47
6.3.5 MASS SPECTROMETERS 48
6.3.6 OTHER GLYCOMICS INSTRUMENTS 49
6.4 KITS 50
6.4.1 GLYCAN LABELING KITS 51
6.4.2 GLYCAN PURIFICATION KITS 52
6.4.3 GLYCAN RELEASE KITS 52
6.4.4 OTHER GLYCOMICS KITS 53
6.5 REAGENTS 54
6.5.1 GLYCOPROTEINS 55
6.5.2 MONOSACCHARIDES 56
6.5.3 OLIGOSACCHARIDES 56
6.5.4 OTHER REAGENTS 57
7 GLYCOMICS MARKET, BY APPLICATION 58
7.1 INTRODUCTION 59
7.2 DIAGNOSTICS 60
7.3 DRUG DISCOVERY & DEVELOPMENT 61
7.4 ONCOLOGY 62
7.5 IMMUNOLOGY 64
7.6 OTHER APPLICATIONS 65
 
8 GLYCOMICS MARKET, BY END USER 67
8.1 INTRODUCTION 68
8.2 ACADEMIC RESEARCH INSTITUTES 69
8.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 70
8.4 CONTRACT RESEARCH ORGANIZATIONS 71
9 GLYCOMICS MARKET, BY REGION 73
9.1 INTRODUCTION 74
9.2 NORTH AMERICA 75
9.2.1 U.S. 80
9.2.2 CANADA 81
9.3 EUROPE 82
9.3.1 GERMANY 86
9.3.2 FRANCE 88
9.3.3 U.K. 89
9.3.4 ITALY 89
9.3.5 SPAIN 91
9.3.6 ROE 92
9.4 ASIA 93
9.4.1 CHINA 99
9.4.2 JAPAN 100
9.4.3 INDIA 101
9.4.4 REST OF ASIA 101
9.5 REST OF THE WORLD (ROW) 102
9.5.1 SOUTH AMERICA 106
9.5.2 MIDDLE EAST AND AFRICA 107
9.5.3 PACIFIC AND OCEANIA 108
10 COMPETITIVE LANDSCAPE 109
10.1 OVERVIEW 109
10.2 MARKET SHARE ANALYSIS 110
10.2.1 GLYCOMICS ENZYMES, KITS, AND REGENTS 110
10.2.2 GLYCOMICS INSTRUMENTS 111
10.3 COMPETITIVE SITUATION AND TRENDS 113
10.3.1 PRODUCT LAUNCHES 114
10.3.2 EXPANSIONS 115
10.3.3 AGREEMENTS 116
10.3.4 ACQUISITIONS, COLLABORATIONS, APPROVALS, AND OTHERS 117
 
11 COMPANY PROFILES 118
(Overview, Products and Services, Financials, Strategy & Development)*
11.1 INTRODUCTION 118
11.2 MERCK KGAA 119
11.3 TAKARA BIO, INC. 122
11.4 SHIMADZU CORPORATION 124
11.5 BRUKER CORPORATION 128
11.6 WATERS CORPORATION 132
11.7 NEW ENGLAND BIOLABS INC. 136
11.8 AGILENT TECHNOLOGIES, INC. 138
11.9 DANAHER CORPORATION 141
11.10 PROZYME, INC. 143
11.11 THERMO FISHER SCIENTIFIC, INC. 146
*Details on Overview, Products and Services, Financials, Strategy & Development might not be Captured in case of Unlisted Companies.
12 APPENDIX 149
12.1 INSIGHTS OF INDUSTRY EXPERTS 149
12.2 DISCUSSION GUIDE 150
12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 153
12.4 INTRODUCING RT: REAL TIME MARKET INTELLIGENCE 155
12.5 AVAILABLE CUSTOMIZATIONS 156
12.6 RELATED REPORTS 157
12.7 AUTHOR DETAILS 158